Welcome to our dedicated page for Innovent Biologi news (Ticker: IVBIY), a resource for investors and traders seeking the latest updates and insights on Innovent Biologi stock.
Innovent Biologics, Inc. develops, manufactures and commercializes biopharmaceutical medicines for oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas. News from Innovent centers on product approvals and commercial updates in China, clinical and preclinical data for pipeline assets, medical-congress presentations, and partner-reported development updates. Recurring drug and program references include mazdutide for type 2 diabetes, IBI363 in cancer immunotherapy, IBI324/OLN324 for retinal disease, tigulixostat/IBI128 for gout, and immunology assets such as picankibart/IBI112, IBI3013 and IAR129.
Innovent Biologics announced that the ORIENT-32 Phase 3 trial of TYVYT® (sintilimab injection) combined with BYVASDA® (bevacizumab biosimilar injection) for treating advanced hepatocellular carcinoma met primary endpoints of progression-free survival (PFS) and overall survival (OS). This interim analysis showed significant improvements over sorafenib, with a safety profile consistent with prior studies. Innovent plans to discuss these results with the National Medical Products Administration in China to potentially advance treatment options for HCC patients.
Innovent Biologics and Eli Lilly presented biomarker results from the ORIENT-11 study at the ESMO Virtual Congress 2020. The trial evaluated TYVYT® (sintilimab injection) combined with ALIMTA® (pemetrexed) for first-line treatment of advanced nonsquamous non-small cell lung cancer (nsqNSCLC). Biomarker analysis indicated that the MHC-II pathway is linked to better progression-free survival (HR, 0.41; P=0.0041), suggesting its potential as a predictive marker. The Chinese NMPA has accepted a supplemental NDA for this combination therapy, indicating a significant step in cancer treatment advancements.
Innovent Biologics and Eli Lilly presented results from the ORIENT-12 study at the ESMO Virtual Congress 2020. This Phase 3 trial evaluated TYVYT® (sintilimab injection) combined with GEMZAR® and platinum chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (sqNSCLC). The study enrolled 357 patients and showed a significant improvement in progression-free survival (PFS) with TYVYT® compared to placebo. The median PFS was 5.5 months for the treatment group versus 4.9 months for placebo, indicating a promising clinical outcome with no new safety signals reported.
Innovent and Eli Lilly announce the presentation of six clinical studies for TYVYT® (sintilimab injection) at the upcoming ESMO Virtual Congress 2020 from September 19-21. Key studies include Phase 3 trials for lung cancer and hepatocellular carcinoma, showing positive preliminary efficacy. Innovations include the combination of sintilimab with various chemotherapy agents, providing insights into patient selection and treatment outcomes. The collaboration between Innovent and Lilly emphasizes a strong partnership in advancing oncology treatments.
Innovent Biologics has received approval from China's National Medical Products Administration for SULINNO® (adalimumab injection), a biosimilar treatment aimed at rheumatoid arthritis, ankylosing spondylitis, and psoriasis. This marks Innovent's third monoclonal antibody approval, expanding its product range beyond oncology. With around 20 million patients in China suffering from these conditions, SULINNO® aims to offer a more affordable alternative to existing therapies, thus improving access and quality of life for patients.
Innovent Biologics has announced the completion of first healthy subject dosing in its Phase I clinical trial (CIBI112A101) for IBI112, a recombinant anti-interleukin 23p19 subunit antibody. This randomized, double-blind, placebo-controlled trial aims to evaluate the safety and tolerability of IBI112 in healthy Chinese subjects. IBI112 targets IL-23, playing a pivotal role in autoimmune diseases such as psoriasis and inflammatory bowel disease. Innovent aims to address significant unmet medical needs in these conditions, with promising preclinical data supporting the drug's efficacy and safety.
Innovent Biologics reported the successful presentation of Phase 1 and Phase 2 clinical study results for Tafolecimab (IBI306) at the European Society of Cardiology conference. The monoclonal antibody demonstrated a satisfactory safety and efficacy profile, with LDL-C reduction rates reaching -52.2% to -72.1% in healthy subjects and -54.30% to -72.26% in hypercholesterolemic patients. Tafolecimab, recognized as a domestically developed PCSK9 inhibitor, offers a longer dosing interval compared to existing treatments, thereby presenting a promising option for patients with high cardiovascular risks.
Innovent Biologics reported a significant revenue increase of 184.9% in H1 2020, totaling RMB984.2 million, driven mainly by TYVYT® sales at RMB920.9 million. The company launched BYVASDA®, its second commercial product, and received approval for strategic drug applications. Collaborations with Roche and Eli Lilly are pivotal, particularly with a US$1 billion agreement for TYVYT® outside China. However, gross profit margins slightly decreased to 81.2%. Despite RMB608.2 million in losses, cash reserves stand strong at US$875 million.
Innovent Biologics and Eli Lilly have expanded their strategic alliance for TYVYT® (sintilimab injection), an anti-PD-1 monoclonal antibody for cancer treatment. Innovent will receive a $200 million upfront payment and up to $825 million in potential milestones, with Lilly obtaining exclusive rights to TYVYT outside of China. TYVYT is already approved in China for relapsed Hodgkin's lymphoma and is included in the National Reimbursement Drug List. The recent interim analysis from the Phase 3 ORIENT-11 trial showed significant improvement in progression-free survival for TYVYT in combination with chemotherapy.